Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
- Blood Clotting
- Technical Know How
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 291124
Licensor shall not engage in, or enable any third party to engage in, any commercialization, licensing, manufacturing, marketing or sales activity with respect to the application of Licensor Know-how or the Licensed Process to Integrelin with or on behalf of any third party without Licensees prior written consent. This agreement includes a non-exclusive grant back to Licensor from Licensee.
Licensee owns certain patent rights, trademarks and know-how relating to a product called Integrelin(TM).
Bulk Product shall mean a bulk peptide product which contains Integrelin, is produced by the Licensed Process and is intended to undergo further processing, formulation and/or vialing and packaging.
Integrelin shall mean a specific peptide designated by Licensee and known as Integrelin(TM),
IPSCIO Record ID: 282942
Eptifibatide shall refer to a specific peptide designated by Licensee and known as eptifibatide, which same peptide was known previously as Integrilin or Integrelin, the chemical structure of which is known to Licensor because of the prior business relationship between Licensee and Licensor.
Integrilin is used to prevent blood clots or heart attack in people with severe chest pain or other conditions, and in those who are undergoing a procedure called angioplasty (to open blocked arteries).
IPSCIO Record ID: 372507
— the Licensor Patents, and the Licensor Know How, existing on the Secondary Source Effective Date, and any patents, including inventors certificates, applications, substitutions, extensions, reissues, re-examinations, renewals, divisions, continuations or continuations-in-part derived from such License Patents or which claim such Solvay Know-How, whenever issued, and
— any License Improvement existing on the Secondary Source Effective Date, for the sole purpose of manufacturing, producing and supplying, and performing development activities related thereto, to Licensee and to any Licensee Affiliate or Sublicensee, the Bulk Drug Substance, and/or drug product containing, or made using, the Bulk Drug Substance, whether in finished, partially finished or bulk form.
Secondary Source is for the production of Bulk Drug Substance through the Licensed Process, and supply of the same to Licensee, its Affiliates and Sublicensees.
Omiganan Drug Substance shall mean any bulk peptide product that contains omiganan pentahydrochloride.
The product is used for certain indications, including the topical administration to a burn site or a surgical wound site for the treatment or prevention in humans of burn-related or surgery-related infections; and the topical administration to a device or the site around the device for the treatment or prevention in humans of device-related infections, including local catheter site infection and catheter related blood stream infection.
The Letter of intent would perform certain development studies on omiganan pentahydrochloride, and further develop a commercial process for the production of the same, and would supply commercial quantities of omiganan pentahydrochloride to Licensee.